Synthetic Biologics Inc (SYN) Sees Significant Decrease in Short Interest

Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 278,160 shares, a decrease of 57.6% from the October 15th total of 655,659 shares. Approximately 9.3% of the company’s stock are short sold. Based on an average daily trading volume, of 412,730 shares, the short-interest ratio is presently 0.7 days.

SYN has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Synthetic Biologics in a research report on Thursday, August 9th. Zacks Investment Research raised Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Tuesday, August 14th.

Shares of SYN opened at $0.84 on Friday. Synthetic Biologics has a one year low of $0.77 and a one year high of $26.60.

Synthetic Biologics (NYSEAMERICAN:SYN) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.39.

COPYRIGHT VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Sees Significant Decrease in Short Interest” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/10/synthetic-biologics-inc-syn-sees-significant-decrease-in-short-interest.html.

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

See Also: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply